Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Abstract: The present invention relates to a TLR3 agonist for use for inducing apoptosis in senescent cancer cells, in particular to a TLR3 agonist for use as a medicament for inducing apoptosis in senescent cancer cells. In particular, it relates to a TLR3 agonist for use for the treatment of cancer, optionally in combination with a chemotherapeutic agent or with radiotherapy. It further relates to a pharmaceutical composition comprising a TLR3 agonist and a chemotherapeutic agent.

Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.

Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.

Abstract: The present invention relates to a drug comprising separately or together (i) a TLR3 ligand and (ii) a chemotherapeutic agent that acts on the intrinsic apoptotic pathway, for simultaneous or sequential administration in the treatment of cancer, wherein the chemotherapeutic agent is selected from topoisomerase II inhibitors, platinum-derived alkylating agents and PI3 kinase inhibitors.

Abstract: Some types of cancer cells express one or more Toll-like receptors (TLRs). These TLRs are therapeutic targets. The invention relates to methods for treating Toll-like receptor expressing cancers and tumor cells by selecting a TLR expressing tumor cell and contacting the cell with a therapeutically effective amount of a TLR ligand. The invention particularly relates to methods for treating TLR3 expressing cancers and tumor cells using TLR3 agonists.

Abstract: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

Abstract: A pharmaceutical composition suitable for administration to human beings in the prevention or treatment of immunologic disorders includes: an immune complex of an antigen and a purified antibody specific thereto, the antigen being selected from a group consisting of antigens that cause pathogenic immunologic reactions in autoimmune disease and graft rejections, and the antigen and antibody being present in a ratio whereby the antibody blocks essentially all binding sites of the antigen; and a pharmacologically acceptable carrier or diluent. The invention also provides a method of administering the composition for treatment of autoimmune disease and treatment or prevention of graft rejections.

Abstract: Some types of cancer cells express one or more Toll-like receptors (TLRs). These TLRs are therapeutic targets. The invention relates to methods for treating Toll-like receptor expressing cancers and tumor cells by selecting a TLR expressing tumor cell and contacting the cell with a therapeutically effective amount of a TLR ligand. The invention particularly relates to methods for treating TLR3 expressing cancers and tumor cells using TLR3 agonists.

Abstract: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

Abstract: CTLA-8 antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.

Abstract: Purified mammalian DC cell surface protein, designated Langerin, nucleic acids encoding Langerin, and antibodies which specifically bind Langerin.

Abstract: In the treatment of allergy, desensitization is effected by administering the allergen in admixture with an antibody thereto, the antibody being present in a molar excess. The antibody is preferably one raised in the patient.